Sarah Tasian

Sarah K Tasian, MD PhD is a pediatric oncologist and physician-scientist at the Children’s Hospital of Philadelphia (CHOP) and an Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine who is interested in development of molecularly-targeted therapeutics and immunotherapies for children with high-risk leukemias. She specialises in the clinical care of children with leukemia and lymphoma, is an internationally-recognized expert in pediatric ALL and AML biology and novel therapeutics, and serves as Chief of the Hematologic Malignancies Program at CHOP, where she holds the Joshua Kahan Endowed Chair in Pediatric Leukemia Research. Her federally-funded translational laboratory research program focuses upon preclinical and early-phase clinical testing of small molecule inhibitors and chimeric antigen receptor (CAR) T cell immunotherapies in high-risk genetic subsets of childhood ALL, AML, and JMML. As an experienced clinical trialist, Dr Tasian also has several leadership roles in the Children’s Oncology Group ALL and Myeloid Diseases executive committees and is the clinical trials leader of the international Blood Cancer United PedAL consortium, working collaboratively with colleagues across the world to advance precision medicine therapeutics for children with relapsed/refractory leukemias.